A groundbreaking Phase II clinical trial has revealed that a new drug, lorundrostat, may offer significant hope to individuals with treatment-resistant high blood pressure.
The peer-reviewed study, recently published in the New England Journal of Medicine, demonstrated that patients receiving lorundrostat experienced an average reduction of 15 mmHg in systolic blood pressure—more than twice the reduction seen in the placebo group.
This discovery, led by scientists from the University of California, San Diego School of Medicine, targets one of the most common chronic health conditions in the U.S., where nearly 120 million adults are affected by hypertension.
Key takeaways from the clinical trial
- Participants receiving lorundrostat showed a 15-point drop in systolic blood pressure.
- The placebo group recorded an average reduction of 7 points, indicating a significant therapeutic benefit.
- The drug works by inhibiting aldosterone, a hormone that contributes to resistant hypertension.
- Over 285 patients participated in the multicenter trial across the U.S., including patients from UC San Diego Health and Cleveland Clinic.
- A Phase III trial is already planned, aiming to validate results on a broader population.
Contents
What Is Lorundrostat and How Does It Work?
Lorundrostat is an investigational aldosterone synthase inhibitor—a drug designed to block the production of aldosterone, a hormone that raises blood pressure by increasing salt retention and vascular tension.
Unlike general antihypertensives, lorundrostat directly targets hormonal imbalances in patients whose blood pressure remains uncontrolled despite conventional treatment.
This mechanism makes it a potential game-changer for those with resistant hypertension, a subtype affecting millions of patients worldwide.
The Structure of the Clinical Trial
The trial was carefully designed to isolate the drug’s true impact.
- All 285 participants began with a three-week period of standardized antihypertensive treatment to establish a baseline.
- After this phase, 190 individuals were randomized to receive lorundrostat, while 95 received a placebo.
- Blood pressure was measured using 24-hour ambulatory monitoring at the start, midpoint, and end of the 12-week period.
This method eliminated external variability and helped researchers confirm the direct effect of lorundrostat on systolic readings.
Results: Clinically Significant Blood Pressure Reductions
The trial showed that:
- Patients receiving lorundrostat consistently achieved larger reductions in systolic pressure, averaging 15 mmHg.
- Placebo patients experienced smaller decreases, around 7 mmHg, likely due to the background medication.
Although some participants’ readings remained above optimal levels, the overall impact of lorundrostat was deemed statistically and clinically significant, particularly for a population that had previously failed to respond to other drugs.
A New Direction in Hypertension Treatment
According to Dr. Michael Wilkinson, the lead investigator and a cardiologist at UC San Diego Health:
“We were specifically studying a new approach to addressing imbalanced aldosterone, which is an often underrecognized cause for treatment-resistant hypertension.”
Dr. Wilkinson emphasized that many study participants had struggled to manage their hypertension with existing options.
Lorundrostat’s performance indicates that targeting aldosterone could become a central strategy in future treatment protocols, especially for underserved or difficult-to-treat populations.
Population Diversity and Future Outlook
A notable feature of the trial was its inclusivity: it involved patients from varied backgrounds, making the findings more applicable across diverse ethnic and socio-economic groups—an often-missing component in cardiovascular studies.
The next step is a Phase III clinical trial, aiming to validate the safety and effectiveness of lorundrostat in a larger, more heterogeneous patient population.
If results remain consistent, the drug could gain regulatory approval as a first-in-class treatment for resistant hypertension.
